Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.
| MER Indicator |
MER description |
Target Fiscal Year |
Target |
| HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female |
2017 |
104,076 |
| HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female |
2017 |
198,240 |
| HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male |
2017 |
44,604 |
| HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male |
2017 |
84,960 |
| HTS_TST |
Number of individuals who received T&C services for HIV and received their test results during the past 12 months |
2017 |
148,680 |
| HTS_TST |
Number of individuals who received T&C services for HIV and received their test results during the past 12 months |
2017 |
283,200 |
| HTS_TST |
Service Delivery Point (Facility): Index testing |
2017 |
997 |
| HTS_TST |
Service Delivery Point (Facility): Index testing |
2017 |
735 |
| HTS_TST |
Service Delivery Point (Facility): Inpatient |
2017 |
5,761 |
| HTS_TST |
Service Delivery Point (Facility): Inpatient |
2017 |
11,198 |
| HTS_TST |
Service Delivery Point (Facility): Other PITC |
2017 |
66,875 |
| HTS_TST |
Service Delivery Point (Facility): Other PITC |
2017 |
144,226 |
| HTS_TST |
Service Delivery Point (Facility): Outpatient |
2017 |
13,443 |
| HTS_TST |
Service Delivery Point (Facility): Outpatient |
2017 |
26,131 |
| HTS_TST |
Service Delivery Point (Facility): PMTCT |
2017 |
58,068 |
| HTS_TST |
Service Delivery Point (Facility): PMTCT |
2017 |
92,137 |
| HTS_TST |
Service Delivery Point (Facility): TB Clinics |
2017 |
2,349 |
| HTS_TST |
Service Delivery Point (Facility): TB Clinics |
2017 |
3,819 |
| HTS_TST |
Service Delivery Point (Facility): VCT |
2017 |
1,187 |
| HTS_TST |
Service Delivery Point (Facility): VCT |
2017 |
4,954 |
| HTS_TST |
Sum of Aggregated Age/Sex 15+ |
2017 |
148,680 |
| HTS_TST |
Sum of Aggregated Age/Sex 15+ |
2017 |
283,200 |
| HTS_TST |
Sum of Aggregated Age/Sex disaggregates |
2017 |
148,680 |
| HTS_TST |
Sum of Aggregated Age/Sex disaggregates |
2017 |
283,200 |
| HTS_TST_POS |
Test Result by Aggregated Age and Sex: Positive 15+ Female |
2017 |
314 |
| HTS_TST_POS |
Test Result by Aggregated Age and Sex: Positive 15+ Female |
2017 |
201 |
| HTS_TST_POS |
Test Result by Aggregated Age and Sex: Positive 15+ Male |
2017 |
413 |
| HTS_TST_POS |
Test Result by Aggregated Age and Sex: Positive 15+ Male |
2017 |
274 |
| KP_MAT |
Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months |
2017 |
380 |
| KP_MAT |
Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months |
2017 |
430 |
| KP_MAT |
Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months |
2017 |
155 |
| KP_MAT |
Sex: Female |
2017 |
35 |
| KP_MAT |
Sex: Female |
2017 |
24 |
| KP_MAT |
Sex: Female |
2017 |
44 |
| KP_MAT |
Sex: Male |
2017 |
345 |
| KP_MAT |
Sex: Male |
2017 |
406 |
| KP_MAT |
Sex: Male |
2017 |
111 |
| KP_MAT |
Sum of Sex Disaggregates |
2017 |
380 |
| KP_MAT |
Sum of Sex disaggregates |
2017 |
430 |
| KP_MAT |
Sum of Sex disaggregates |
2017 |
155 |
| KP_PREV |
By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) |
2017 |
34 |
| KP_PREV |
By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) |
2017 |
53 |
| KP_PREV |
By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) |
2017 |
420 |
| KP_PREV |
By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) |
2017 |
122 |
| KP_PREV |
Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required |
2017 |
454 |
| KP_PREV |
Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required |
2017 |
175 |
| KP_PREV |
Total estimated number of key population in the catchment area |
2017 |
4,485 |
| KP_PREV |
Total estimated number of key population in the catchment area |
2017 |
18,500 |
| KP_PREV_den |
By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area) |
2017 |
895 |
| KP_PREV_den |
By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area) |
2017 |
3,495 |
| KP_PREV_den |
By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area) |
2017 |
3,590 |
| KP_PREV_den |
By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area) |
2017 |
15,005 |
| TB_SCREENDX |
[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB |
2017 |
93 |
| TB_SCREENDX |
[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB |
2017 |
130 |
| TB_SCREENDX |
[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only |
2017 |
85 |
| TB_SCREENDX |
[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only |
2017 |
117 |
| TB_SCREENDX |
[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay |
2017 |
8 |
| TB_SCREENDX |
[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay |
2017 |
13 |
| TB_SCREENDX |
Screen Result: Screened Positive for TB |
2017 |
132 |
| TB_SCREENDX |
Screen Result: Screened Positive for TB |
2017 |
184 |
| TB_SCREENDX |
Screened for TB by Age/Sex: 15+ Female |
2017 |
1,330 |
| TB_SCREENDX |
Screened for TB by Age/Sex: 15+ Female |
2017 |
886 |
| TB_SCREENDX |
Screened for TB by Age/Sex: 15+ Male |
2017 |
1,993 |
| TB_SCREENDX |
Screened for TB by Age/Sex: 15+ Male |
2017 |
1,722 |
| TB_SCREENDX |
The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period |
2017 |
3,323 |
| TB_SCREENDX |
The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period |
2017 |
2,608 |
| TX_CURR |
Aggregated Age/Sex: 15+ Female |
2017 |
886 |
| TX_CURR |
Aggregated Age/Sex: 15+ Female |
2017 |
1,330 |
| TX_CURR |
Aggregated Age/Sex: 15+ Male |
2017 |
1,722 |
| TX_CURR |
Aggregated Age/Sex: 15+ Male |
2017 |
1,993 |
| TX_CURR |
Number of adults and children receiving antiretroviral therapy (ART) |
2017 |
2,608 |
| TX_CURR |
Number of adults and children receiving antiretroviral therapy (ART) |
2017 |
3,323 |
| TX_CURR |
Sum of Aggregated Age/Sex 15+ |
2017 |
2,608 |
| TX_CURR |
Sum of Aggregated Age/Sex 15+ |
2017 |
3,323 |
| TX_CURR |
Sum of Aggregated Age/Sex disaggregates |
2017 |
2,608 |
| TX_CURR |
Sum of Aggregated Age/Sex disaggregates |
2017 |
3,323 |
| TX_NEW |
Aggregated Grouping by Age/Sex: 15+ Female |
2017 |
550 |
| TX_NEW |
Aggregated Grouping by Age/Sex: 15+ Female |
2017 |
845 |
| TX_NEW |
Aggregated Grouping by Age/Sex: 15+ Male |
2017 |
1,072 |
| TX_NEW |
Aggregated Grouping by Age/Sex: 15+ Male |
2017 |
1,267 |
| TX_NEW |
Number of adults and children newly enrolled on antiretroviral therapy (ART) |
2017 |
1,622 |
| TX_NEW |
Number of adults and children newly enrolled on antiretroviral therapy (ART) |
2017 |
2,112 |
| TX_NEW |
Sum of Aggregated Age/Sex disaggregates |
2017 |
1,622 |
| TX_NEW |
Sum of Aggregated Age/Sex disaggregates |
2017 |
2,112 |
| TX_PVLS |
Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months |
2017 |
1,798 |
| TX_PVLS |
Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months |
2017 |
1,814 |
| TX_PVLS |
Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months |
2017 |
1,619 |
| TX_PVLS |
Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months |
2017 |
1,633 |
| TX_PVLS |
Numerator Aggregated Age/Sex: 15+ Female |
2017 |
486 |
| TX_PVLS |
Numerator Aggregated Age/Sex: 15+ Female |
2017 |
490 |
| TX_PVLS |
Numerator Aggregated Age/Sex: 15+ Male |
2017 |
1,133 |
| TX_PVLS |
Numerator Aggregated Age/Sex: 15+ Male |
2017 |
1,143 |
| TX_PVLS |
Numerator: Indication: Routine |
2017 |
1,457 |
| TX_PVLS |
Numerator: Indication: Routine |
2017 |
1,469 |
| TX_PVLS |
Numerator: Indication: Targeted |
2017 |
162 |
| TX_PVLS |
Numerator: Indication: Targeted |
2017 |
164 |
| TX_PVLS_den |
Denominator Aggregated Age/Sex: 15+ Female |
2017 |
540 |
| TX_PVLS_den |
Denominator Aggregated Age/Sex: 15+ Female |
2017 |
545 |
| TX_PVLS_den |
Denominator Aggregated Age/Sex: 15+ Male |
2017 |
1,258 |
| TX_PVLS_den |
Denominator Aggregated Age/Sex: 15+ Male |
2017 |
1,269 |
| TX_PVLS_den |
Denominator: Indication: Routine |
2017 |
1,619 |
| TX_PVLS_den |
Denominator: Indication: Routine |
2017 |
1,633 |
| TX_PVLS_den |
Denominator: Indication: Targeted |
2017 |
179 |
| TX_PVLS_den |
Denominator: Indication: Targeted |
2017 |
181 |
| TX_RET |
Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2017 |
160 |
| TX_RET |
Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2017 |
93 |
| TX_RET |
Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2017 |
319 |
| TX_RET |
Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2017 |
140 |
| TX_RET |
Number of adults and children who are still alive and on treatment at 12 months after initiating ART |
2017 |
479 |
| TX_RET |
Number of adults and children who are still alive and on treatment at 12 months after initiating ART |
2017 |
233 |
| TX_RET |
Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up |
2017 |
600 |
| TX_RET |
Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up |
2017 |
291 |
| TX_RET_den |
Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2017 |
202 |
| TX_RET_den |
Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2017 |
135 |
| TX_RET_den |
Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2017 |
398 |
| TX_RET_den |
Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2017 |
156 |
